Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer
ConclusionsThe use of continuous models provides a statistically better fit than TTD groupings, without the need for strong assumptions about the health states experienced by patients. Where a TTD approach is merited for use in modelling, continuous functions should be considered, with the scope for further improvements in statistical fit by both widening the number of candidate models tested and the therapeutic areas investigated. (Source: PharmacoEconomics)
Source: PharmacoEconomics - September 14, 2023 Category: Health Management Source Type: research
Correction: Belimumab for Treating Active Autoantibody ‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
(Source: PharmacoEconomics)
Source: PharmacoEconomics - September 4, 2023 Category: Health Management Source Type: research
Modelling Spillover Effects on Informal Carers: The Carer QALY Trap
AbstractThe provision of informal (unpaid) care can impose significant ‘spillover effects’ on carers, and accounting for these effects is consistent with the efficiency and equity objectives of health technology assessment (HTA). Inclusion of these effects in health economic models, particularly carer health-related quality of life (QOL), can have a substantial imp act on net quality-adjusted life year (QALY) gains and the relative cost effectiveness of new technologies. Typically, consideration of spillover effects improves the value of a technology, but in some circumstances, consideration of spillover effects can l...
Source: PharmacoEconomics - September 2, 2023 Category: Health Management Source Type: research
Informal Caregiving Provision for Disabled or Elderly in the Families and Work Productivity: Evidence from 11 Waves of an Australian Population-Based Cohort
ConclusionOur study reveals that working-age caregivers experience greater absenteeism, presenteeism and working hour tension. Adverse effects of informal caregiving are required to perform the cost effectiveness of an intervention given to caregivers to improve carer and patient health. Our findings will assist health technology assessment (HTA) practitioners in performing an economic evaluation of interventions given to caregivers by providing the indirect cost (productivity loss) of caregiving. (Source: PharmacoEconomics)
Source: PharmacoEconomics - September 1, 2023 Category: Health Management Source Type: research
Productivity Loss Across Socioeconomic Groups Among Patients With Low Back Pain or Osteoarthritis: Estimates Using the Friction-Cost Approach in Norway
DiscussionSocioeconomic status and model design are sources of variation in PL. In health economic applications with PL and in patient populations with large socioeconomic differences, adjusting for these factors may be as important as sensitivities in parameters such as the friction length. (Source: PharmacoEconomics)
Source: PharmacoEconomics - September 1, 2023 Category: Health Management Source Type: research
Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis
ConclusionsLow-density lipoprotein-cholesterol lowering from early ages is a more cost-effective strategy than late intervention and cost effectiveness increased with the increasing lifetime risk of coronary heart disease. (Source: PharmacoEconomics)
Source: PharmacoEconomics - August 22, 2023 Category: Health Management Source Type: research
The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations
This study has investigated these three issues for ordered inputs bounded between 0 and 1. An analytic solution is given that allows for more straightforward and compact implementation. The difference method approach cannot always be applied to a set of three or more model inputs, and this depends on the relative size of the variances of the logit-transformed Beta distributions fitted to each variable. The approach can also produce samples with biased means and variances under certain combinations of input means and variances. It is recommended that the difference method approach be used where appropriate; however, an unde...
Source: PharmacoEconomics - August 21, 2023 Category: Health Management Source Type: research
Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada
ConclusionWe found that PGx-based warfarin for patients with AF is cost-effective at a WTP threshold of C$50,000/QALY. Apixaban had a higher probability of being cost-effective (> 50%) at a WTP threshold of C$93,000/QALY. (Source: PharmacoEconomics)
Source: PharmacoEconomics - August 19, 2023 Category: Health Management Source Type: research
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies
ConclusionsContrary to cost-of-illness analyses, most of the included economic evaluations did not account for the hidden burden of rare diseases, that is, costs borne by patients, families, and societies. Including these types of costs in future studies would provide a more comprehensive picture of the burden of disease, providing empirical data to inform how we value and make decisions regarding rare disease interventions, health policy, and resource allocation. (Source: PharmacoEconomics)
Source: PharmacoEconomics - August 18, 2023 Category: Health Management Source Type: research
Multiplier Effects and Compensation Mechanisms for Inclusion in Health Economic Evaluation: A Systematic Review
ConclusionWhile our review suggests that compensation mechanisms and multiplier effects may have a significant impact on productivity losses and costs, much remains unclear about their features, valid measurement, and correct valuation. This hampers their current inclusion in economic evaluation, and therefore, more research into both phenomena remains warranted. (Source: PharmacoEconomics)
Source: PharmacoEconomics - August 17, 2023 Category: Health Management Source Type: research
Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom
The objective of this study was to quantify the value of ceftazidime –avibactam for treating gram-negative infections in the UK considering some of these broader value elements unique to antimicrobials.MethodsA previously developed dynamic disease transmission and cost-effectiveness model was applied to assess the value of introducing ceftazidime-avibactam to UK treatment practice in the management of gram-negative hospital-acquired infections in line with the licenced indications for ceftazidime –avibactam. Model inputs were parameterised using sources aligned to the UK perspective.ResultsThe introduction of ceftazidi...
Source: PharmacoEconomics - August 16, 2023 Category: Health Management Source Type: research
